Chinese team releases results of animal experiments on new coronavirus vaccine

Qin Chuan, director of the Institute of Medical Experimental Animals of the Chinese Academy of Medical Sciences, Zhang Jing, a researcher at the Institute of Microbiology of the Center for Disease Control and Prevention of Zhejiang Province, Kexing Holdings, Wang Xiangxi, a researcher at the Institute of Biophysics of the Chinese Academy of Sciences, Li Changgui, a researcher at the China Food and Drug Research Institute, and Lu Jinxing, a researcher at the Institute of Infectious Disease Prevention and Control of the Chinese Center for Disease Control and Prevention, are the authors of the newsletterKexing Holdings Gao Qiang, DrBao Linlin of the Chinese Academy of Medical Sciences, DrMao Haiyan of the Zhejiang Provincial Center for Disease Control and Prevention, Wang Lin of Kexing Holdings, DrXu Kangwei of the China Food and Drug Research Institute, and DrYang Yannan of the Institute of Biophysics of the Chinese Academy of Sciences are the co-authors of the paperThe COVID-19 pandemic caused by theof the new coronavirus has brought unprecedented crisis to people, poses a great threat to human health and life, and has caused catastrophic damage to the global economyTo date, there have been no effective antiviral drugs against the new coronavirus, so there is an urgent need to rapidly develop effective new coronavaccinesThe researchers isolated several new coronavirus strains from 11 hospitalized patients , including five ICU patients, from a broncholicosic irrigation fluid, including five from China, three from Italy and one from Switzerland, the United Kingdom and SpainThese 11 strains are scattered extensively in the development of systems based on all available sequences, to some extent representing the epidemic virus populationresearchers selected CN2 strains for vaccine preparation, developed a purified inactivated new coronavirus candidate vaccine, and piloted productionThe vaccine can induce neo-coronavirus-specific neutralizing antibody production in mice, rats, and non-human primatesThese antibodies effectively neutralise the other 10 selected strains (CN1, CN3-CN5, and OS1-OS6) that represent the representative new coronavirus strain, indicating that they may have potential neutrality and capabilities for the new coronavirus strain, which is widespread worldwideThen the researchers conducted a poison test in the rhesus monkey after the vaccine was immunized to evaluate the vaccine's immunogenicity and protection effectThe researchers gave different doses of the vaccine to rhesus monkeys on days 0, 7 and 14, and the results showed that S-protein-specific IgG and neutralizing antibodies were induced in week 2 and were poisoned on the 22nd day after vaccinationThe results showed that the pathological changes of lung tissue in rhesus monkeys after vaccination were significantly reduced and the viral load decreased significantly compared with the control group No virus was detected in the throat, anus and lungs in the 7th day after infection in the high-dose group of rhesus monkeys, and no increased antibody dependence was observed to provide complete protection against the new coronavirus attack The researchers also verified the vaccine's safety by observing clinical indicators and biochemical indexes, and found that all vaccinated rhesus monkeys did not find fever or weight loss, and that appetite and mental state remained normal In blood and biochemical analysis, there was no significant change in the proportion of lymphocytes in the vaccinated rhesus monkeys and the key cytokines compared to the control group A pathological assessment of various organ tissues in the lungs, heart, spleen, liver, kidneys and brain of the vaccinated rhesus monkeyons on the 29th day showed that the vaccine did not cause significant pathological characteristics, and the above results showed that the vaccine was safe in rhesus monkeys based on the above results, the State Drug Administration approved the vaccine for clinical study on April 13, phase I clinical study was officially launched on April 16 in Yanning County, Xuzhou City, Jiangsu Province, the first batch of volunteers have successfully entered the group and completed the first vaccination.